Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities

Tezepelumab, a thymic stromal lymphopoietin antagonist, was approved by the FDA in December 2021 (Tezspire) as add-on maintenance therapy for patients with severe asthma whose symptoms remain uncontrolled on guideline-recommended therapy. Approval was based on findings from the phase 3 NAVIGATOR study.

In a presentation at the annual American Academy of Asthma, Allergy, & Immunology meeting, Tara Carr, MD, presented results of a post hoc analysis of NAVIGATOR data that assesed the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma and common respiratory comorbidities. Carr spoke with Patient Care Online about the analysis and implications for primary care practice.

Tara F. Carr, MD is associate professor of medicine and otolaryngology, director, Adult Allergy Program and director, Allergy & Immunology Fellowship Program, Asthma and Airway Disease Research Center, at the University of Arizona College of Medicine in Tucson, Arizona.